These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26262364)

  • 1. Data Science Solution to Event Prediction in Outsourced Clinical Trial Models.
    Dalevi D; Lovick S; Mann H; Metcalfe PD; Spencer S; Hollis S; Ruau D
    Stud Health Technol Inform; 2015; 216():1065. PubMed ID: 26262364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data.
    Sarangdhar M; Tabar S; Schmidt C; Kushwaha A; Shah K; Dahlquist JE; Jegga AG; Aronow BJ
    Nat Biotechnol; 2016 Jul; 34(7):697-700. PubMed ID: 27404875
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical methods for the analysis of adverse event data.
    Kieser M
    Pharm Stat; 2016 Jul; 15(4):290-1. PubMed ID: 27324410
    [No Abstract]   [Full Text] [Related]  

  • 4. Human factors and medical IT systems: complex incident reporting systems and multiple IV infusions.
    Colvin C; Baird P; Easty T; Trbovich P
    Biomed Instrum Technol; 2013; Suppl():59-63. PubMed ID: 24111773
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool.
    Hébert G; Netzer F; Ferrua M; Ducreux M; Lemare F; Minvielle E
    Eur J Cancer; 2015 Feb; 51(3):427-35. PubMed ID: 25549531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the performance characteristics of signals used by a clinical event monitor to detect adverse drug reactions in the nursing home.
    Handler SM; Hanlon JT; Perera S; Saul MI; Fridsma DB; Visweswaran S; Studenski SA; Roumani YF; Castle NG; Nace DA; Becich MJ
    AMIA Annu Symp Proc; 2008 Nov; 2008():278-82. PubMed ID: 18998853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription-event monitoring and reporting of adverse drug reactions.
    Heeley E; Riley J; Layton D; Wilton LV; Shakir SA
    Lancet; 2001 Dec; 358(9296):1872-3. PubMed ID: 11741629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The way towards adverse event monitoring in clinical trials.
    Wallander MA
    Drug Saf; 1993 Mar; 8(3):251-62. PubMed ID: 8452665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-Based Monitoring: Key Conditions in Collaboration Between Contract Research Organization and Sponsor.
    Wolfs M; Bambic A; Lange BS; Galante K; Plaza RS; O'Conallain C; Racaro G; Giblin M; Djali S
    Ther Innov Regul Sci; 2019 Jul; 53(4):512-518. PubMed ID: 30157695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
    Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
    Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extraction Of Adverse Events From Clinical Documents To Support Decision Making Using Semantic Preprocessing.
    Gaebel J; Kolter T; Arlt F; Denecke K
    Stud Health Technol Inform; 2015; 216():1030. PubMed ID: 26262330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine use of the "ADE scorecards", an application for automated ADE detection in a general hospital.
    Chazard E; Luyckx M; Beuscart JB; Ferret L; Beuscart R
    Stud Health Technol Inform; 2013; 192():308-12. PubMed ID: 23920566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of heterogeneity in distributed research network drug safety analyses.
    Hansen RA; Zeng P; Ryan P; Gao J; Sonawane K; Teeter B; Westrich K; Dubois RW
    Res Synth Methods; 2014 Dec; 5(4):352-70. PubMed ID: 26052957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of medication safety and clinical outcomes related to drug interaction software.
    Wong K; Yu S; Holbrook A
    AMIA Annu Symp Proc; 2008 Nov; ():1179. PubMed ID: 18999164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring and managing adverse drug reactions.
    Fincham JE
    Am Pharm; 1992 Feb; NS32(2):74-81. PubMed ID: 1546634
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event.
    Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ
    Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787
    [No Abstract]   [Full Text] [Related]  

  • 19. Continuous event monitoring via a Bayesian predictive approach.
    Di J; Wang D; Brashear HR; Dragalin V; Krams M
    Pharm Stat; 2016; 15(2):109-22. PubMed ID: 26643012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wonder vigilance.
    Edwards IR
    Drug Saf; 2010 Feb; 33(2):83-6. PubMed ID: 20088622
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.